Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis

Table 4 Variation in promotion and research and development spending by individual company by year

Company	Promotion spending on drugs in 50 most promoted ($000)				Research and development spending ($000)
Company	2013	2014	2015	2016	2013	2014	2015	2015
Abbott EPD	15,779	16,009	8104	–	0	0	0	–
Actavis	–	3034	2753	–	–	20	0	–
Allergan	–	–	–	2328	–	–	–	1751
Amgen	5816	5836	6515	6359	50,370	45,622	42,153	38,600
Astellas	3006	3097	8094	5612	4735	3447	6952	3851
AstraZeneca	20,066	35,416	33,655	41,304	13,781	24,273	41,143	61,468
Bayer	10,857	11,995	11,486	11,898	23,476	31,373	39,719	45,025
BGP Pharma	–	–	–	4809	–	–	–	0
BMS Pharma	20,081	13,132	7588	14,741	53,270	45,001	59,456	81,335
Boehringer Ingelheim	11,570	17,304	14,147	24,961	23,476	18,430	22,742	21,409
GlaxoSmithKline	19,384	30,547	13,328	27,567	88,350	77,648	53,413	43,326
Janssen	5636	12,666	16,839	6356	49,983	61,733	70,646	86,380
Leo	3847	–	–	–	939	–	–	–
Lilly	12,358	8261	7592	6150	53,672	26,620	22,277	36,710
Lundbeck	9956	3322	12,146	8900	888	2596	3126	0
Merck	27,682	13,065	18,441	36,963	19,962	26,505	21,667	32,582
Novartis	3460	7838	5376	12,002	106,013	78,553	51,916	44,701
Novo Nordisk	6536	4159	3517	3580	4563	10,857	7886	4548
Paladin	–	–	3113	–	–	–	265	–
Pfizer	24,429	12,009	12,178	14,162	24,643	14,174	8953	9738
Purdue	9996	3790	6099	2666	13,581	14,683	12,609	16,321
Sanofi-Aventis	3222	2870	–	3578	19,940	13,847	–	8450
Servier	7862	14,134	8893	7252	11.745	13,612	8067	7150
Shire	4145	6967	3287	3464	281	350	0	0
Takeda	14,099	13,415	19,582	5460	0	0	0	0
Valeant	3633	3535	7414	8251	0	0	14,231	9712

ISSN: 2052-3211